Circulating hepatocyte growth factor level but not basic fibroblast growth factor level is elevated in angiography-proven symptomatic peripheral artery disease

Angiology

Volumn 58, Issue 4, 2007, Pages 420-428

  Lin, Jiunn Wen ^a   Sheu, Wayne Huey Herng ^a,b   Lee, Wen Jane ^a   Chen, Ying Tsung ^a,b   Liu, Tsun Jui ^a,c   Ting, Chih Tai ^a,c   Lee, Wen Lieng ^a,c  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; SCATTER FACTOR;

AGED; ANGIOGRAPHY; ARTERY DISEASE; ARTERY OCCLUSION; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; SERUM;

AGED; ANGIOGRAPHY; ARTERIAL OCCLUSIVE DISEASES; BIOLOGICAL MARKERS; CORONARY DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FEMORAL ARTERY; FIBROBLAST GROWTH FACTOR 2; FOLLOW-UP STUDIES; HEPATOCYTE GROWTH FACTOR; HUMANS; ILIAC ARTERY; MALE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 34548119570     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319706294556     Document Type: Article

References (34)

1. Hiatt WR: Medical treatment of peripheral arterial disease and claudication. N Engl J Med 344 (21). 1608-1621, 2001.
2. Isner JM: Therapeutic angiogenesis: a new frontier for vascular therapy. Vasc Med 1 (1). 79-87, 1996.
3. Nakamura T.: Structure and function of hepatocyte growth factor. Prog Growth Factor Res 3 (1). 67-85, 1991.
4. Bauters C., Six I., Meurice T., Van Belle E: Growth factors and endothelial dysfunction. Drugs 59 (spec no.)11-15, 1999.
5. Nishimura M., Ushiyama M., Nanbu A.,, et al. Serum hepatocyte growth factor as a possible indicator of arteriosclerosis. J Hypertens 15 (10). 1137-1142, 1997.
6. Tateishi J., Waku S., Masutani M.,, et al. Hepatocyte growth factor as a potential predictor of the presence of atherosclerotic aorto-iliac artery disease. Am Heart J 143 (2). 272-276, 2002.
7. Yoshitomi Y., Kojima S., Umemoto T.,, et al. Serum hepatocyte growth factor in patients with peripheral arterial occlusive disease. J Clin Endocrinol Metab 84 (7). 2425-2428, 1999.
8. Matsumori A., Furukawa Y., Hashimoto T.,, et al. Increased circulating hepatocyte growth factor in the early stage of acute myocardial infarction. Biochem Biophys Res Commun 221 (2). 391-395, 1996.
9. Rohovsky S., Kearney M., Pieczek A.,, et al. Elevated levels of basic fibroblast growth factor in patients with limb ischemia. Am Heart J 132 (5). 1015-1019, 1996.
10. Nakamura Y., Morishita R., Nakamura S.,, et al. A vascular modulator, hepatocyte growth factor, is associated with systolic pressure. Hypertension 28 (3). 409-413, 1996.
11. Almeda FQ, Parrillo JE, Klein LW: Alternative therapeutic strategies for patients with severe end-stage coronary artery disease not amenable to conventional revascularization. Catheter Cardiovasc Interv 60 (1). 57-66, 2003.
12. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (6). 499-502, 1972.
13. Kannel WB, McGee DL: Update on some epidemiologic features of intermittent claudication: the Framingham Study. J Am Geriatr Soc 33 (1). 13-18, 1985.
14. Stoyioglou A., Jaff MR: Medical treatment of peripheral arterial disease: a comprehensive review. J Vasc Interv Radiol 15 (11). 1197-1207, 2004.
15. Morishita R., Nakamura S., Hayashi S.,, et al. Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy. Hypertension 33 (6). 1379-1384, 1999.
16. Chleboun JO, Martins RN, Mitchell CA,, et al. bFGF enhances the development of the collateral circulation after acute arterial occlusion. Biochem Biophys Res Commun 185 (2). 510-516, 1992.
17. Van BE, Witzenbichler B., Chen D.,, et al. Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis. Circulation 97 (4). 381-390, 1998.
18. Schultz A., Lavie L., Hochberg I.,, et al. Interindividual heterogeneity in the hypoxic regulation of VEGF: significance for the development of the coronary artery collateral circulation. Circulation 100 (5). 547-552, 1999.
19. Arras M., Ito WD, Scholz D.,, et al. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. J Clin Invest 101 (1). 40-50, 1998.
20. Morishita R., Nakamura S., Hayashi S.,, et al. Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy. Hypertension 33 (6). 1379-1384, 1999.
21. Michalopoulos GK, DeFrances MC: Liver regeneration. Science 276 (5309). 60-66, 1997.
22. Nakamura Y., Morishita R., Higaki J.,, et al. Hepatocyte growth factor is a novel member of the endothelium-specific growth factors: additive stimulatory effect of hepatocyte growth factor with basic fibroblast growth factor but not with vascular endothelial growth factor. J Hypertens 14 (9). 1067-1072, 1996.
23. Ono K., Matsumori A., Shioi T., Furukawa Y., Sasayama S.: Enhanced expression of hepatocyte growth factor/ c-Met by myocardial ischemia and reperfusion in a rat model. Circulation 95 (11). 2552-2558, 1997.
24. Kono S., Nagaike M., Matsumoto K., Nakamura T.: Marked induction of hepatocyte growth factor mRNA in intact kidney and spleen in response to injury of distant organs. Biochem Biophys Res Commun 186 (2). 991-998, 1992.
25. Yanagita K., Nagaike M., Ishibashi H.,, et al. Lung may have an endocrine function producing hepatocyte growth factor in response to injury of distal organs. Biochem Biophys Res Commun 182 (2). 802-809, 1992.
26. Nishimura M., Nakano K., Ushiyama M.,, et al. Increased serum concentrations of human hepatocyte growth factor in proliferative diabetic retinopathy. J Clin Endocrinol Metab 83 (1). 195-198, 1998.
27. Matsumori A., Ono K., Furukawa Y., Okada M., Sasayama S.: Circulating hepatocyte growth factor as an early marker of arterial thrombus formation. Jpn Circ J 62 (4). 311-313, 1998.
28. Losordo DW, Dimmeler S.: Therapeutic angiogenesis and vasculogenesis for ischemic disease, part I: angiogenic cytokines. Circulation 109 (21). 2487-2491, 2004.
29. Xu X., Weinstein M., Li C.,, et al. Fibroblast growth factor receptors (FGFRs) and their roles in limb development. Cell Tissue Res 296 (1). 33-43, 1999.
30. Scarborough JE, Smith ML, Domkowski PW,, et al. Basic fibroblast growth factor is upregulated in hibernating myocardium. J Surg Res 107 (1). 119-123, 2002.
31. Palmer-Kazen U., Wariaro D., Luo F.,, et al. Vascular endothelial cell growth factor and fibroblast growth factor 2 expression in patients with critical limb ischemia. J Vasc Surg 39 (3). 621-628, 2004.
32. Sullivan CJ, Doetschman T., Hoying JB: Targeted disruption of the Fgf2 gene does not affect vascular growth in the mouse ischemic hindlimb. J Appl Physiol 93 (6). 2009-2017, 2002.
33. Kawamoto A., Kawata H., Akai Y.,, et al. Serum levels of VEGF and basic FGF in the subacute phase of myocardial infarction. Int J Cardiol 67 (1). 47-54, 1998.
34. Campuzano R., Barrios V., Cuevas B.,, et al. Serum basic fibroblast growth factor levels in exercise-induced myocardial ischemia more likely a marker of endothelial dysfunction than a marker of ischemia? Eur J Med Res 7 (3). 93-97, 2002.